Dr. Yvonne Greenstreet is the CEO of Alnylam Pharmaceuticals, a pioneering company in RNA interference (RNAi) therapeutics. With over 25 years of experience in the biopharmaceutical industry, she has held significant leadership roles at Pfizer and GlaxoSmithKline. Under her guidance, Alnylam continues to innovate and deliver transformative medicines to patients worldwide.
Who is the CEO of Alnylam Pharmaceuticals?
Dr. Yvonne Greenstreet has carved a remarkable path in the biopharmaceutical industry. Before her tenure at Alnylam Pharmaceuticals, she held pivotal roles at Pfizer and GlaxoSmithKline, where she led significant divisions and drove strategic innovation. Joining Alnylam in 2016, she ascended to CEO by 2022, steering the company towards groundbreaking advancements in RNAi therapeutics.
Her leadership is marked by a commitment to diversity, equity, and inclusion, earning her recognition as the 2024 Woman of the Year by the Healthcare Businesswomen’s Association.
Work History
Dr. Yvonne Greenstreet's extensive work history in the biopharmaceutical industry includes notable positions at several leading companies. Here is a summary of her career trajectory:
- Pfizer - Senior Vice President (2006 to 2011)
- GlaxoSmithKline - Senior Vice President and Head of Medicines Development (2011 to 2016)
- Alnylam Pharmaceuticals - Chief Operating Officer (2016 to 2022)
- Alnylam Pharmaceuticals - Chief Executive Officer (2022 to Present)
Education History
Dr. Yvonne Greenstreet's educational journey is as impressive as her professional career. She earned her medical degree from the University of Leeds, where she developed a strong foundation in clinical medicine. Furthering her expertise, she pursued an MBA from INSEAD, one of the world's leading business schools. This combination of medical and business education has equipped her with a unique perspective, enabling her to navigate the complexities of the biopharmaceutical industry with exceptional acumen.
When did Dr. Yvonne Greenstreet join Alnylam Pharmaceuticals?
Dr. Yvonne Greenstreet joined Alnylam Pharmaceuticals in 2016, initially serving as the Chief Operating Officer. She ascended to the role of Chief Executive Officer at the end of 2021. As of 2024, Dr. Greenstreet has been with Alnylam Pharmaceuticals for approximately eight years, leading the company through significant advancements in RNA interference therapeutics. Her tenure as CEO has been marked by a commitment to innovation and a focus on delivering transformative medicines to patients worldwide.